Levi S, Urbano-Ispizua A, Gill R, Thomas D M, Gilbertson J, Foster C, Marshall C J
Section of Cell and Molecular Biology, Chester Beatty Laboratories, Institute of Cancer Research, London, United Kingdom.
Cancer Res. 1991 Jul 1;51(13):3497-502.
By using a modified polymerase chain reaction strategy, we have devised an approach to detect a K-ras oncogene mutated at codon 12 in the presence of 1000 normal alleles. This is a considerable improvement in sensitivity on previous assays. Application of this assay to 15 cholangiocarcinomas showed that all contained a K-ras mutation to codon 12 and that nine of the tumors contained two or more mutations. In 11 cases, mutations were present in less than 10% of the cells in the sample. In common with pancreatic adenocarcinomas, in which 75 to 95% of cases contain a mutation in K-ras, cholangiocarcinomas show a very high frequency of ras gene mutation, but within a tumor only a fraction of cells contain a ras mutation. The presence of multiple mutations and the low frequency of mutant alleles in the samples argue against K-ras mutations being the initiating genetic lesion in this tumor, but suggest that ras gene mutation is involved in the stepwise progression of neoplastic cells to full malignancy.
通过使用改良的聚合酶链反应策略,我们设计了一种方法,可在存在1000个正常等位基因的情况下检测密码子12处发生突变的K-ras癌基因。这在灵敏度上比以前的检测方法有了相当大的提高。将该检测方法应用于15例胆管癌,结果显示所有病例均存在密码子12处的K-ras突变,其中9例肿瘤含有两个或更多突变。在11例病例中,样本中突变细胞少于10%。与75%至95%的病例存在K-ras突变的胰腺腺癌一样,胆管癌显示出非常高的ras基因突变频率,但在肿瘤内只有一小部分细胞含有ras突变。样本中存在多个突变以及突变等位基因的低频率表明,K-ras突变并非该肿瘤起始的遗传损伤,但提示ras基因突变参与了肿瘤细胞逐步发展为完全恶性肿瘤的过程。